Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
Livagen and BAC Water Mix

Livagen Reconstitution Calculator

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example Livagen Titration Schedule

ItemDetails
Standard dose2 mg once daily
Courses10–20 days, 2–3× per year
Originator dose10–1000× lower (Russian tradition)

Exactly one human observation: chromatin activation in lymphocytes of adults aged 75–88 (mechanism confirmation, not an efficacy trial). The '1–5 mg per dose' figure is a recurring placeholder that never matched a validated protocol for any bioregulator; sources disagree up to 1000× on real doses.

Possible vial strengths:

What Is It?

Livagen

Tetrapeptide bioregulator.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix Livagen

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

Livagen Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

Livagen is a Khavinson "bioregulator" — a synthetic tetrapeptide (Lys-Glu-Asp-Ala, KEDA, ~462 Da) built to target liver tissue at the gene level. Its signature effect in the lab is chromatin decondensation: it physically "opens" tightly packed DNA in aged hepatocytes and lymphocytes, reportedly restoring access to genes that fell silent with age. It's sold as an oral/sublingual capsule and as a research-grade injectable powder.
Both are Khavinson liver peptides, but they differ in sequence and scope: Livagen (KEDA, a tetrapeptide) is focused specifically on hepatocyte gene regulation and chromatin opening, while Ovagen (Glu-Asp-Leu, a tripeptide) is a dual-organ regulator covering the liver-gut axis. They share a target organ but supposedly hit different gene sets, which is why some protocols pair them rather than swap one for the other. Livagen is also a close cousin of Vilon (KE) — same N-terminal start, but Vilon is immune-targeted.
In rodent and cell studies, Livagen raised protein synthesis in aged hepatocytes, boosted T-cell markers (CD3+, CD4+, CD8+) and neutrophil activity, and shifted digestive-enzyme activity along the gut-liver axis — effects that were strongest in older, not younger, tissue. The proposed thread is epigenetic: opening age-condensed chromatin so liver and immune genes can fire again. This is preclinical, largely Russian research, so it is not a demonstrated treatment for any liver disease.
Only the injectable research powder needs mixing — the oral or sublingual capsule is taken as-is. For a 20 mg vial, adding 2 mL of bacteriostatic water gives 10 mg/mL, so a 1 mg amount draws to 0.1 mL (10 units on a U-100 syringe); use less water for a more concentrated solution and smaller draws. There's no established injectable human dose, and Khavinson protocols are pulsed (short courses, not daily indefinitely), so any figure is a research choice.
Livagen has no FDA approval and isn't a medicine in Western jurisdictions — it's a research compound or supplement, sourced largely through Russian channels, with no independent safety validation. Even though a tiny tetrapeptide is expected to be low-toxicity, a struggling liver is a serious matter: hepatitis, fatty liver, and cirrhosis need real diagnosis and monitoring, not an unproven peptide, so loop in a clinician before anything. Storage: the lyophilized powder is best kept frozen or at fridge temperature in a dry, dark place, with reconstituted solution used within a short window.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

About the author

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides